← back to search

Wim Quint

European Patent Organisation · NL
Area of research
Epidemiology · Surgery
Research interest
Research interests include Cervical Cancer and HPV Research, Reproductive tract infections research, Head and Neck Cancer Studies, and Genital Health and Disease.
h-index
88
citations
35,089
works
511
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025cited by 0position: contributordoi
Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025cited by 0position: contributordoi
Data from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025cited by 0position: contributordoi
Supplementary Data FS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025cited by 0position: contributordoi
Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025cited by 0position: contributordoi
Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025cited by 0position: contributordoi
Supplementary Data FS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025cited by 0position: contributordoi
Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025cited by 0position: contributordoi
Supplementary Data TS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2025cited by 0position: contributordoi
Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data FS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data MS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data TS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data TS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data TS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data FS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data TS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data FS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Data from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data FS3 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Supplementary Data MS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
2024cited by 0position: contributordoi
Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men.
2023cited by 5position: contributordoi
Supplementary Data FS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2023cited by 0position: contributordoi
Supplementary Data FS2 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2023cited by 0position: contributordoi
Supplementary Data TS1 from Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV<sup>+</sup> Men
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Jan M. Prins · Public Health Service of Amsterdam46 papers (2018–2025)Sjoerd H. van der Burg · Oncode Institute44 papers (2023–2025)Carel J.M. van Noesel · Amsterdam University Medical Centers44 papers (2023–2025)Allard C. van der Wal · Maastricht University Medical Centre44 papers (2023–2025)— · 44 papers (2023–2025)Cornelis J. M. Melief · Leiden University Medical Center44 papers (2023–2025)— · 44 papers (2023–2025)— · 44 papers (2023–2025)Henry JC de Vries · Netherlands Center for Occupational Diseases44 papers (2023–2025)— · 44 papers (2023–2025)— · 44 papers (2023–2025)Marij J. P. Welters · German BioImaging – Gesellschaft für Mikroskopie und Bildanalyse44 papers (2023–2025)Sanne Boekestijn · 44 papers (2023–2025)Wilhelmus J.T.A. Krebber · 44 papers (2023–2025)Karien C.M. Gosens · 44 papers (2023–2025)Olivier Richel · Radboud University Nijmegen44 papers (2023–2025)Nikki M. Loof · Leiden University Medical Center44 papers (2023–2025)Michael Pawlita · Heidelberg University12 papers (2012–2022)Laia Alemany · University of New Mexico11 papers (2014–2020)Silvia de Sanjosé · National Cancer Institute9 papers (2014–2020)